July 12th 2024
“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
AI-Based Model May Guide Decision-Making in Kidney Cancer Based on CT, EGFR
March 17th 2023Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Efforts are Underway to Tackle Immunotherapy Resistance in Refractory RCC
March 14th 2023Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Ipilimumab Yields ‘Limited Effect’ in Refractory Kidney Cancer Subtype
March 12th 2023Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
Expert Highlights Armamentarium of Advanced Kidney Cancer Therapies
March 11th 2023An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Nivolumab Combo Yields PFS Benefit Regardless of PD-L1, c-MET status in RCC
February 21st 2023An ongoing exploratory biomarker analysis of the CheckMate 9ER trial set out to identify predictive biomarkers or a composite model of response of nivolumab/cabozantinib efficacy in advanced renal cell carcinoma.
TFS Improves With Nivolumab, Salvage Nivolumab in Advanced Renal Cell Carcinoma
February 21st 2023Results from cohort A of the HCRN GU16-260 trial showed treatment-free survival was enhanced in patients with advanced renal cell carcinoma who received nivolumab monotherapy plus salvage nivolumab and ipilimumab maintenance.
Cabozantinib Combo Shows Boost in Efficacy in Advanced Kidney Cancer Subgroups
February 18th 2023When combined with nivolumab and ipilimumab, cabozantinib appears to improve outcomes over placebo for patients with advanced, intermediate-risk renal cell cancer, and showed some efficacy among the poor-risk population.